This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Protein radical formation === Glycyl radical enzyme activating enzymes (GRE-AEs) are radical SAM subset that can house a stable and catalytically essential glycyl radical in their active state. The underlying chemistry is considered to be the simplest in the radical SAM superfamily with H-atom abstraction by the 5'-dAdo radical being the product of the reaction. A few examples include:
Droplet countercurrent chromatography (DCCC or DCC) was introduced in 1970 by Tanimura, Pisano, Ito, and Bowman. DCCC is considered to be a form of liquid-liquid separation, which includes countercurrent distribution and countercurrent chromatography, that employs a liquid stationary phase held in a collection of vertical glass columns connected in series. The mobile phase passes through the columns in the form of droplets. The DCCC apparatus may be run with the lower phase stationary and the upper phase being introduced to the bottom of each column. Or it may be run with the upper phase stationary and the lower phase being introduced from the top of the column. In both cases, the work of gravity is allowed influence the two immiscible liquids of different densities to form the signature droplets that rise or descend through the column. The mobile phase is pumped at a rate that will allow droplets to form that maximize the mass transfer of a compound between the upper and lower phases. Compounds that are more soluble in the upper phase will travel quickly through the column, while compounds that are more soluble in the stationary phase will linger. Separation occurs because different compounds distribute differently, in a ratio called the partition coefficient, between the two phases. The biphasic solvent system must be carefully formulated so that it will perform appropriately in the DCCC column. The solvent system must form two phases without excess emulsification in order to form droplets.
=== Destruction and preservation === Because of its waterlogged condition the Flag Fen Basin was an area where peat deposits developed around 2000 BC, and they survive there today. The anaerobic conditions generated by silt deposits from the fens protected the wooden posts and rafters of the collapsed structures from rotting away under the influence of air and bacteria. In the 10th century BC the ground level was much lower than today, increasing around 1 mm (0.039 inches) per year as autumnal debris was added to the surface of the fens. By the early Roman period most of the structure was covered and preserved.
Sources: en.wikipedia.org
== Platforms == Current nanoparticle drug delivery systems can be cataloged based on their platform composition into several groups: polymeric nanoparticles, inorganic nanoparticles, viral nanoparticles, lipid-based nanoparticles, and nanoparticle albumin-bound (nab) technology. Each family has its unique characteristics.
where Vatom = Vcell/n and n is the number of atoms per unit cell of volume Vcell. The unit cell of silicon has a cubic packing arrangement of 8 atoms, and the unit cell volume may be measured by determining a single unit cell parameter, the length a of one of the sides of the cube. The CODATA value of a for silicon is 5.431020511(89)×10−10 m. In practice, X-ray crystallography measurements are carried out on a distance known as d220(Si), which is the distance between the planes denoted by the Miller indices {220}, and is equal to a/√8. The isotope proportional composition of the sample used must be measured and taken into account. Silicon occurs in three stable isotopes (28Si, 29Si, 30Si), and the natural variation in their proportions is greater than other uncertainties in the measurements. The atomic weight Ar for the sample crystal can be calculated, as the standard atomic weights of the three nuclides are known with great accuracy. This, together with the measured density ρ of the sample, allows the molar volume Vm to be determined:
==== Distribution ==== Following a 600 mg oral dose, peak plasma concentrations (Cmax) are achieved in approximately 2 hours under fasting conditions and 4 hours under non-fasting conditions. The presence of food alters absorption; the bioavailability of the tablet formulation decreases by 21–23% under moderate to high-fat conditions relative to fasting conditions. Ritonavir is highly bound (98–99%) to human serum proteins, primarily binding to serum albumin and α1-acid glycoprotein over a concentration range of 0.01 to 30 µg/mL. This extensive protein binding attenuates its free antiviral activity in vitro by approximately 20-fold. The drug exhibits a volume of distribution (Vd) of 0.41 ± 0.25 L/kg.
== Consumer products == There have been cases of severe contact dermatitis which was likely related to a dimethyl fumarate contact allergy of newly acquired sofas and chairs. Dimethyl fumarate has been found to be an allergic sensitizer at very low concentrations, producing eczema by contact allergy that is difficult to treat. Concentrations as low as 1 ppm (parts-per-million) may produce allergic reactions in the most severe cases. There are only a handful of equally potent sensitisers. The sensitizing risk was brought to public attention by the "poison chair" incident, where Chinese manufacturer Linkwise produced two-seater sofas with dimethyl fumarate sachets inside to inhibit mould while they were in storage or transport. In Finland where the chairs were sold from 2006 to 2007, 60 users sustained serious rashes. The cause was identified as dimethyl fumarate-induced allergic reaction by Tapio Rantanen from Finland and his original article became the cover story in the July 2008 issue of the British Journal of Dermatology. In the United Kingdom, sofas sold by Argos, Land of Leather and Walmsley Furnishing containing the chemical caused over a hundred injuries. Argos withdrew the sofas from stores and contacted buyers to collect those that had been sold — with Land of Leather withdrawing the sofas without notifying buyers and Walmsley saying they had removed the sachets from sofas they sold after the danger came to light. The danger came to public attention in 2008 when the BBC Watchdog programme alerted consumers to the sofas.
Sources: en.wikipedia.org
=== Withdrawal === On abrupt or overly rapid discontinuation of lorazepam, anxiety, and signs of physical withdrawal have been observed, similar to those seen on withdrawal from alcohol and barbiturates. Lorazepam, as with other benzodiazepine drugs, can cause physical dependence, addiction, and benzodiazepine withdrawal syndrome. The higher the dose and the longer the drug is taken, the greater the risk of experiencing unpleasant withdrawal symptoms. Withdrawal symptoms can also occur from standard dosages and after short-term use. Benzodiazepine treatment is recommended to be discontinued as soon as possible via a slow and gradual dose reduction regimen. Rebound effects often resemble the condition being treated, but typically at a more intense level and may be difficult to diagnose. Withdrawal symptoms can range from mild anxiety and insomnia to more severe symptoms such as seizures and psychosis. The risk and severity of withdrawal are increased with long-term use, use of high doses, abrupt or over-rapid reduction, among other factors. Short-acting benzodiazepines, such as lorazepam, are more likely to cause a more severe withdrawal syndrome compared to longer-acting benzodiazepines. Withdrawal symptoms can occur after taking therapeutic doses of lorazepam for as little as one week.
Caridad del Rosario Diego Bello, the head of the Office of Religious Affairs, then held a private meeting with a group of Freemasons. She told them that she had no knowledge about anything that had been happening, but encouraged everyone to abide by the Ministry of Justice so that the fraternity could continue to operate in Cuba.
=== Classification === Diabetic foot ulcer is a complication of diabetes. Diabetic foot ulcers are classified as either neuropathic, neuroischaemic or ischaemic. Doctors also use the Wagner Grades to describe the severity of an ulcer. The purpose of the Wagner Grades is to allow specialists to better monitor and treat diabetic foot ulcers. This grading system classifies Diabetic foot ulcers using numbers, from 0 to 5. Wagner Grades 0 through 5 are as follows:
==== Physical ==== Heavy, long-term exposure to marijuana may have physical, mental, behavioral and social health consequences. It may be "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". A 2014 review found that while cannabis use may be less harmful than alcohol use, the recommendation to substitute it for problematic drinking was premature without further study. Various surveys conducted between 2015 and 2019 found that many users of cannabis substitute it for prescription drugs (including opioids), alcohol, and tobacco; most of those who used it in place of alcohol or tobacco either reduced or stopped their intake of the latter substances. Cannabinoid hyperemesis syndrome (CHS) is a severe condition seen in some chronic cannabis users where they have repeated bouts of uncontrollable vomiting for 24–48 hours. Four cases of death have been reported as a result of CHS. A limited number of studies have examined the effects of cannabis smoking on the respiratory system. Chronic heavy marijuana smoking is associated with respiratory infections, coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis. The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease. Short-term use of cannabis is associated with bronchodilation. Other side effects of cannabis use include cannabinoid hyperemesis syndrome (CHS), a condition which involves recurrent nausea, cramping abdominal pain, and vomiting.
=== Sympathetic skin response === Sympathetic skin response (SSR) refers to the change in skin resistance to electrical conduction associated with the sympathetic activation of sudomotor function in response to external or internal stimuli, such as electrical stimulation, deep breathing, and mental stress. It is mediated by a poorly understood somato-sympathetic reflex with spinal, bulbar, and suprabulbar components. The SSR is frequently utilized in psychophysiological studies and is a well-known component of the polygraph test. The test is performed using standard electromyography (EMG) equipment in a lightly dimmed, humidity- and temperature-controlled room. A surface electrode is positioned on the patient's palm or sole, along with a reference electrode on the dorsal side of the same body area. A change in skin potential is then induced either through electrical stimulation or deep breathing. The recorded SSR is then plotted on a graph and analyzed for presence or absence, latency, and amplitude. The SSR is thought to be mainly influenced by the electrolyte content of sweat secreted from eccrine glands. In addition, there is significant intra-individual and inter-individual variability, and SSR declines with age and is commonly absent in individuals over the age of 50. SSR is only considered a surrogate marker of sudomotor function and its results should be interpreted in the context of other sudomotor testing.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.